TIDMGEN
Company Announcement
COPENHAGEN, Denmark; August 15, 2023 --
https://www.globenewswire.com/Tracker?data=AEIZumLqFHQ8V1tcTe0Btz9OV3Qsgjb3LT5zExGoKZfalw2c765mwQulHWaAaSYLuVgSUFNHEqzk6FBb1Ijtvw==
Genmab A/S (Nasdaq: GMAB) will increase its share capital by 18,700
shares as a consequence of the exercise of employee warrants.
The increase is effected without any preemption rights for the
existing shareholders of the company or others. The shares are
subscribed in cash at the following price per share of nominally
DKK 1:
963 shares at DKK 962.00,
1,525 shares at DKK 1,136.00,
1,635 shares at DKK 1,145.00,
1,671 shares at DKK 1,147.50,
100 shares at DKK 1,155.00,
500 shares at DKK 1,161.00,
870 shares at DKK 1,334.50,
200 shares at DKK 1,408.00,
9,956 shares at DKK 1,615.00, and
1,280 shares at DKK 1,948.00.
Proceeds to the company are approximately DKK 27.2 million. The
increase corresponds to approximately 0.03% of the company's share
capital.
The new shares are ordinary shares without any special rights
and are freely transferable negotiable instruments. The new shares
give rights to dividends and other rights in relation to the
company as of subscription. The new shares will be listed on Nasdaq
Copenhagen after registration with the Danish Business Authority.
The capital increase is expected to be finalized shortly.
Pursuant to section 32 of the Danish Capital Markets Act No. 41
of January 13, 2023, it is hereby announced that the total nominal
value of Genmab A/S' share capital after the capital increase is
DKK 66,057,125 which is made up of 66,057,125 shares of a nominal
value of DKK 1 each, corresponding to 66,057,125 votes.
About Genmab
Genmab is an international biotechnology company with a core
purpose guiding its unstoppable team to strive towards improving
the lives of patients through innovative and differentiated
antibody therapeutics. For more than 20 years, its passionate,
innovative and collaborative team has invented next-generation
antibody technology platforms and leveraged translational research
and data sciences, which has resulted in a proprietary pipeline
including bispecific T-cell engagers, next-generation immune
checkpoint modulators, effector function enhanced antibodies and
antibody-drug conjugates. To help develop and deliver novel
antibody therapies to patients, Genmab has formed 20+ strategic
partnerships with biotechnology and pharmaceutical companies. By
2030, Genmab's vision is to transform the lives of people with
cancer and other serious diseases with Knock-Your-Socks-Off (KYSO)
antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark with locations in Utrecht, the Netherlands, Princeton, New
Jersey, U.S. and Tokyo, Japan. For more information, please visit
https://www.globenewswire.com/Tracker?data=AEIZumLqFHQ8V1tcTe0Bt4HNkaU6rraO-vZGL3V5J0rs_1IGMP54PQBWpR8CTakrZBV25lTD2zxhJegmQFOcOw==
Genmab.com and follow us on
https://www.globenewswire.com/Tracker?data=pJgc8pnXT59Ek-Nqwg5ODnDKslFZMKWaS8ccMFhPsPpSdKtp5Ft4facivcB3Bvu46uPZGHSLIVUZefv7kMkbm1ECox23bVe8wawGojEckjw=
Twitter.com/Genmab.
Contact:
Marisol Peron, Senior Vice President, Global Communications
& Corporate Affairs
T: +1 609 524 0065; E:
https://www.globenewswire.com/Tracker?data=o43u3qe0s_BaIGrUt-OJDnFZR_RX_aPnk0ciUD_f2HUOEK4OopC83Y3zpLfbNGRy5NsIqqWYdINnf14MCN4VTg==
mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E:
https://www.globenewswire.com/Tracker?data=JdLw5I3ImT4gPWfytyZ9KTmNDqbJXg9Gp0Bpvpj3_Cfem4HgEgOeBY3VX3HDL4E60eXIrugHoQV3280qtvmF5Q==
acn@genmab.com
This Company Announcement contains forward looking statements.
The words "believe", "expect", "anticipate", "intend" and "plan"
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab's most recent financial reports, which are
available on
https://www.globenewswire.com/Tracker?data=XVfplPuL0EAhHici6UBjb5vmwCzS019HGlQEFCQyH4C5Xdys15AYP4Dh89ZcvqlgKsdPydEk71s6Vs2LyzguhQ==
www.genmab.com and the risk factors included in Genmab's most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available at
https://www.globenewswire.com/Tracker?data=XVfplPuL0EAhHici6UBjb6idD2tMAhE8rajLTEgC-X9lOKdiKckewsBNw4mxMBdCsLSOUxkyWMpoSieSk_40mH7XWOn1V7Tq6mzFsE3Sg7Y=
www.sec.gov. Genmab does not undertake any obligation to update or
revise forward looking statements in this Company Announcement nor
to confirm such statements to reflect subsequent events or
circumstances after the date made or in relation to actual results,
unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination
with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ;
HexaBody(R) ; DuoHexaBody(R) and HexElect(R) .
Company Announcement no. 38
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark
Attachment
-- 230815_CA38_Warrant Exercise
https://ml-eu.globenewswire.com/Resource/Download/3ae6287f-e366-461d-8352-a624857c1b59
(END) Dow Jones Newswires
August 15, 2023 13:09 ET (17:09 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Genuit (LSE:GEN)
Historical Stock Chart
From Dec 2024 to Jan 2025
Genuit (LSE:GEN)
Historical Stock Chart
From Jan 2024 to Jan 2025
